Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263036 | 0.94 | TLR8 (0.37) | TLR8TLR7TLR9PTGER4NPY5R | |
| SCHEMBL262977 | 0.93 | PTGER4 (0.38) | PTGER4NPY5RTSPO | |
| SCHEMBL262242 | 0.92 | TLR8 (0.38) | TLR8TLR7TLR9PTGER4NPY5R | |
| SCHEMBL262860 | 0.91 | NPY5R (0.37) | PTGER4NPY5RTSPO | |
| SCHEMBL262783 | 0.86 | CTSV (0.41) | PTGER4NPY5RTSPO | |
| SCHEMBL11920661 | 0.86 | KIF11 (0.36) | TLR8TLR7TLR9 | |
| SCHEMBL262846 | 0.85 | KDM4E (0.41) | TLR8TLR7TLR9PTGER4NPY5R | |
| SCHEMBL262716 | 0.84 | KDM4E (0.42) | PTGER4NPY5RTSPO | |
| SCHEMBL263033 | 0.84 | KIF11 (0.43) | PTGER4NPY5RCCKBRTSPO | |
| SCHEMBL263024 | 0.83 | PTGS2 (0.38) | TLR8TLR7TLR9PTGER4NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530672-B2 | Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20120309984-A1 | ORGANIC COMPOUND, ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING ANTHRACENE DERIVATIVE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309984-A1 | ORGANIC COMPOUND, ANTHRACENE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE USING ANTHRACENE DERIVATIVE | CYP1A1, XPO7, AMY1A | SLC5A1 4606/4885TLR8 3410/4885TLR7 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.